The 52nd annual meeting of the American Society of Hematology (ASH) will kick off this Saturday, December 4, in Orlando. Experts from around the world will present the latest research about various blood diseases, including multiple myeloma, and The Myeloma Beacon will provide comprehensive coverage of the meeting as it happens.

“The Myeloma Beacon will be a one-stop source for myeloma-related news from the ASH meeting,” said Boris Simkovich, publisher of The Myeloma Beacon.

Similar to the Beacon’s coverage of …

Just over four years ago, a very good friend of mine, named Gene, dropped by my real estate office on a Saturday morning.

My partner Bruce and I greeted Gene warmly. A fellow Realtor, Gene had committed to joining our real estate team later that year.

Unfortunately, we soon discovered Gene had not stopped in to talk shop. No, Gene was on his way home from seeing an oncologist. Gene had just learned he had prostate cancer.

To make …

The 52nd annual meeting of the American Society of Hematology will take place Saturday, December 4, through Tuesday, December 7.

During the four-day meeting, clinical specialists from all over the world will discuss current research regarding the diagnosis and treatment of various blood diseases, including multiple myeloma. Over 20,000 people are expected to attend the event.

The American Society of Hematology (ASH) meeting will include many presentations and posters focused on myeloma. The ASH website currently lists about 350 myeloma-related …

The Myeloma Beacon is pleased to announce the addition of physician columns to its website.

Each column will be written by a physician who specializes in the treatment of multiple myeloma. The columns will provide Beacon readers with insights into the treatment of multiple myeloma, perspectives on important myeloma-related topics, and thoughts on recent developments in the field.

“We recognize that Beacon readers are particularly interested in reading about myeloma experts’ perspectives,” said Maike Haehle, associate publisher of The Myeloma …

I was diagnosed with multiple myeloma during December of 2003 at a time just before social networking and blogging took off. I spent a lot of days hospitalized without Internet access. I look back and think about what a nice diversion and support it may have been to be able to connect with others via the Internet.

As I recovered and moved beyond illness to my “new normal” life, I lost track of much of the medical terminology of my …

GlaxoSmithKline has announced that it is halting all further development of its proprietary formulation of resveratrol known as SRT501.

A key factor in this decision, according to the company, was that it no longer feels the drug offers an adequate efficacy / safety trade-off as a potential treatment for multiple myeloma.

Earlier this year, Glaxo suspended its Phase 2 trial of SRT501 in multiple myeloma because several patients in the trial developed kidney failure.

At …

According to a recent study, myeloma patients with the chromosomal abnormalities del(1p21) or del(17p) had shorter time to disease progression and lower overall survival rates while taking Revlimid-dexamethasone therapy than patients without those abnormalities.

Chromosomal abnormalities result from structural changes of the chromosome.  These changes may occur through deletions, insertions, duplications, or movement of chromosomal regions. Chromosomal abnormalities are considered high-risk factors in multiple myeloma and have been an area of intensive research because they may render patients less responsive …